DE69327755D1 - Zusammensetzung zum Unterdrücken von Infektion und Wachstum des menschlichen Immunschwäche-Virus unter Verwendung eines eisenbindenden Proteins - Google Patents

Zusammensetzung zum Unterdrücken von Infektion und Wachstum des menschlichen Immunschwäche-Virus unter Verwendung eines eisenbindenden Proteins

Info

Publication number
DE69327755D1
DE69327755D1 DE69327755T DE69327755T DE69327755D1 DE 69327755 D1 DE69327755 D1 DE 69327755D1 DE 69327755 T DE69327755 T DE 69327755T DE 69327755 T DE69327755 T DE 69327755T DE 69327755 D1 DE69327755 D1 DE 69327755D1
Authority
DE
Germany
Prior art keywords
growth
composition
binding protein
immunodeficiency virus
human immunodeficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69327755T
Other languages
English (en)
Other versions
DE69327755T2 (de
Inventor
Wataru Motsuchi
Shigeaki Tanaka
Shunichi Dosako
Hiroshi Shinmoto
Naoki Yamamoto
Hideki Nakashima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Snow Brand Milk Products Co Ltd
Original Assignee
Snow Brand Milk Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Snow Brand Milk Products Co Ltd filed Critical Snow Brand Milk Products Co Ltd
Publication of DE69327755D1 publication Critical patent/DE69327755D1/de
Application granted granted Critical
Publication of DE69327755T2 publication Critical patent/DE69327755T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69327755T 1992-07-28 1993-07-27 Zusammensetzung zum Unterdrücken von Infektion und Wachstum des menschlichen Immunschwäche-Virus unter Verwendung eines eisenbindenden Proteins Expired - Lifetime DE69327755T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP04220635A JP3100005B2 (ja) 1992-07-28 1992-07-28 ヒト免疫不全ウィルス感染・増殖抑制剤

Publications (2)

Publication Number Publication Date
DE69327755D1 true DE69327755D1 (de) 2000-03-09
DE69327755T2 DE69327755T2 (de) 2000-11-23

Family

ID=16754065

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69327755T Expired - Lifetime DE69327755T2 (de) 1992-07-28 1993-07-27 Zusammensetzung zum Unterdrücken von Infektion und Wachstum des menschlichen Immunschwäche-Virus unter Verwendung eines eisenbindenden Proteins

Country Status (4)

Country Link
US (1) US5725864A (de)
EP (1) EP0584558B1 (de)
JP (1) JP3100005B2 (de)
DE (1) DE69327755T2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3100005B2 (ja) * 1992-07-28 2000-10-16 雪印乳業株式会社 ヒト免疫不全ウィルス感染・増殖抑制剤
JP3312946B2 (ja) * 1993-03-04 2002-08-12 雪印乳業株式会社 ウイルス感染・増殖抑制剤
DE4419256A1 (de) * 1994-06-01 1995-12-07 Rau Freiherr Von Nagell Helmut Verwendung von intravenös applizierbarem Eisen zur Therapie von Tumorerkrankungen und/oder Infektionskrankheiten
DE4421159C1 (de) * 1994-06-20 1995-08-24 Thomas Bruns Verwendung von Eisen(III)-oxid (Fe¶2¶O¶3¶) bei Immunschwäche
WO1996002255A1 (fr) * 1994-07-15 1996-02-01 Taiyo Kagaku Co., Ltd. Composition medicamenteuse contenant un derive d'acide sialique
US5985275A (en) * 1995-04-12 1999-11-16 New York Blood Center β-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection
US5952009A (en) * 1996-03-20 1999-09-14 New York Blood Center Methods for preventing the transmission of or treating patients infected with herpesvirus
US5869446A (en) * 1996-07-09 1999-02-09 Gambit International Limited Preparation of lactoferrin (or serotransferrin or ovotransferrin) and desferrioxamine methanesulfonate (or other low molecular weight metal ion chelators) for the therapy of viral infections
JP2002515893A (ja) * 1997-02-03 2002-05-28 ファーミング インテレクチュアル プロパティ ビーブイ ヒトラクトフェリンおよびその改変体の有用な特性
JP2002508009A (ja) * 1998-04-13 2002-03-12 ニュー イングランド メディカル センター ホスピタル インク． ラクトフェリンおよび関連分子を用いた感染性因子を不活化する方法および組成物
DE19844022C1 (de) * 1998-09-25 2000-05-25 Sherif Sabry Ragab Mekkawi Verwendung von eisenbindenden Glycoproteinen und/oder 10-Hydroxy-2-decensäure in Verbindung mit Thymochinon zur Behandlung von AIDS
US6156349A (en) * 1998-12-14 2000-12-05 Steinbach, Pylant And Herman, L.L.C. Method of treating HIV infection with suppository containing mammalian liver extract
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US6491826B1 (en) * 1999-10-12 2002-12-10 Marine Biotech Incorporated Systems and methods for separation of organics from fluids
AU1436901A (en) * 1999-10-22 2001-05-08 American Health Sciences, Inc. Treatment and prevention of herpes simplex infections
JP4683740B2 (ja) 2001-02-15 2011-05-18 明治乳業株式会社 炎症に伴う症状の軽減剤
US20030191193A1 (en) 2002-04-03 2003-10-09 Jillian Cornish Lactoferrin
EP1576964A4 (de) * 2002-11-29 2008-06-11 Morinaga Milk Industry Co Ltd Protease-hemmer
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
CN101600441A (zh) * 2006-06-01 2009-12-09 治疗剂肽有限公司 聚合生物表面活性剂
BR122018002612B8 (pt) 2006-06-13 2021-07-27 Helix Biomedix Inc tetrapeptídeo capaz de induzir a produção das proteínas da matriz extracelular e composição o compreendendo
US20100215631A1 (en) * 2006-06-14 2010-08-26 Anita Hartog Anti-inflammatory composition comprising glycine and lactoferrin and the use thereof
JP2009221159A (ja) * 2008-03-17 2009-10-01 Yokohama Tlo Co Ltd Ｐｅｇ化ラクトフェリンを主成分とする医薬製剤
FR2944016B1 (fr) * 2009-04-02 2012-03-09 Isp Investments Inc Nouveaux peptides anti-age activateurs du proteasome et compositions les contenant
FR2944015B1 (fr) * 2009-04-02 2012-03-09 Isp Investments Inc Nouveaux peptides eclaircissants activateurs du proteasome et compositions les contenant
KR102275125B1 (ko) * 2019-10-29 2021-07-07 건국대학교 산학협력단 난백 오보트랜스페린 효소 가수분해물을 포함하는 면역증강용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448762A (en) * 1980-11-03 1984-05-15 The United States Of America As Represented By The United States Department Of Energy Complex of transferrin with ruthenium for medical applications
JPH0732718B2 (ja) * 1985-01-18 1995-04-12 クマ−ル ガウリ，カイラツシユ 蛋白加水分解物およびその製造法
US4977137B1 (en) * 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
FR2626472B1 (fr) * 1988-02-02 1991-06-14 Roussel Uclaf Utilisation des proteines du lait pour la fabrication d'un medicament antiviral
CA1331191C (en) * 1988-03-25 1994-08-02 Bengt Ronny Andersson Therapeutically useful tetralin derivatives
AU636104B2 (en) * 1989-01-09 1993-04-22 Meiji Milk Products Co., Ltd. Anti-hiv agent
US5198419A (en) * 1989-12-08 1993-03-30 Immuno Japan Inc. Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria
EP0438750B1 (de) * 1990-01-23 1993-10-27 Morinaga Milk Industry Co., Ltd. Laktoferrinhydrolysat zur Verwendung als antibakterielles Mittel
EP0603187A4 (en) * 1991-05-31 1995-08-30 Us Health Human lactoferrin.
DE69322896T2 (de) * 1992-03-02 1999-05-27 Japan Immuno Inc Verwendung von Proteinen der Transferrin/Lactoferrin-Familie zur Stimulation des Immunsystems
JP3100005B2 (ja) * 1992-07-28 2000-10-16 雪印乳業株式会社 ヒト免疫不全ウィルス感染・増殖抑制剤

Also Published As

Publication number Publication date
US5725864A (en) 1998-03-10
JP3100005B2 (ja) 2000-10-16
EP0584558A3 (de) 1994-12-21
EP0584558A2 (de) 1994-03-02
JPH0648956A (ja) 1994-02-22
EP0584558B1 (de) 2000-02-02
DE69327755T2 (de) 2000-11-23

Similar Documents

Publication Publication Date Title
DE69327755T2 (de) Zusammensetzung zum Unterdrücken von Infektion und Wachstum des menschlichen Immunschwäche-Virus unter Verwendung eines eisenbindenden Proteins
ATE250424T1 (de) Zusammensetzungen und verfahren zur anregung des wachstums von neuriten
DE69942708D1 (de) Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
DK57391D0 (da) Hiv proteiner og peptider til anvendelse ved diagnosticering, profylakse og behandling af aids
DE69622074D1 (de) Cystin-Silikon-Copolymere und deren Verwendung zur Behandlung von keratinischen Materialien
DE59000652D1 (de) Verwendung von umsetzungsprodukten von alkenylspirobislactonen und aminen als paraffindispergatoren.
DE69325451T2 (de) Verwendung von pyruvamid und ausgewählten pyruvyl-aminosäuren
AU3727695A (en) Compositions and methods for the abrogation of cellular proliferation utilizing the human immunodeficiency virus vpr protein
DE69515070T2 (de) Zusammensetzung auf der Basis von alpha-Pyronen zur Induzierung und Stimulierung des Haarwachstums und/oder zur Verlangsamung des Haarausfalls und ihre Verwendung
ATE290315T1 (de) Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
DE69430121D1 (de) Verfahren und zusammemsetzungen aehnlich den bindungsprotein des sterol-regulationselements
DE69716896D1 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
DE59611383D1 (de) Darreichungsform zur applikation von pharmazeutischen wirkstoffen und hilfsstoffen und verfahren zur herstellung derselben
DE59007794D1 (de) Verfahren zur Herstellung von 2-Chlor-5-chlormethyl-pyridin und neue Zwischenprodukte.
DE59310073D1 (de) Verfahren zur Inaktivierung von Viren in Präparationen von Proteinen
ATE211928T1 (de) Verfahren zur inaktivierung von viren in proteinen
DE69017825T2 (de) Heilverfahren von Lebererkrankungen mit Verwendung von Pyrrol-Chinolin-Chinone-Triester und neue Pyrrol-Chinolin-Chinone-Triester.
DE69434914D1 (de) Verfahren und zusammensetzungen zur herstellung von rekombinantem osteogenischem protein
DE69428610D1 (de) Methoden zur kultivierung von infektiösem laryngotracheitis virus und von "egg-drop-syndrome" verursachendem virus
DE3777022D1 (de) Verfahren und praeparat zur inaktivierung von viren.
DE9018171U1 (de) Anordnung zur Verwendung von insbesondere magnetischen Vektorpotentialien zur Behandlung von Materialien
DE59510416D1 (de) Verfahren zur Herstellung von Chlormethylpyridin Derivaten und Acylaminomethylpyridine als Zwischenprodukte
DE68926511T2 (de) Verfahren zur diagnostizierung von viralen und genetischen krankheiten
DE68908404T2 (de) Lang haltende zusammensetzung von propafenon und chinidin zur behandlung des zustandes des herzens.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition